
Joseph M Unger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4880812/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of Clinical Oncology, 2023, 41, 336-342.	0.8	9
2	Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. JCO Oncology Practice, 2022, 18, e442-e451.	1.4	5
3	Unequal impact of the COVID-19 pandemic on paediatric cancer care: a population-based cohort study in China. The Lancet Regional Health - Western Pacific, 2022, 19, 100347.	1.3	9
4	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. Journal of the National Cancer Institute, 2022, 114, 372-380.	3.0	28
5	Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. Journal of Clinical Oncology, 2022, 40, 1474-1486.	0.8	102
6	Patterns of Scientific and Clinical Impact in Cancer Randomized Clinical Trials. JAMA Network Open, 2022, 5, e2219657.	2.8	1
7	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. Journal of the National Cancer Institute, 2021, 113, 54-63.	3.0	98
8	Caregiver engagement practices in National Cancer Institute Clinical Oncology Research Program settings: Implications for research to advance the field. Cancer, 2021, 127, 639-647.	2.0	13
9	"When Offered to Participate†A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. Journal of the National Cancer Institute, 2021, 113, 244-257.	3.0	116
10	Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials. JAMA Oncology, 2021, 7, 131.	3.4	36
11	Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. Journal of the National Cancer Institute, 2021, 113, 989-996.	3.0	13
12	Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare. Blood Cancer Discovery, 2021, 2, 119-124.	2.6	27
13	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncology, 2021, 7, 246.	3.4	34
14	Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 66-78.	1.8	23
15	Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. Journal of Clinical Oncology, 2021, 39, 1339-1348.	0.8	62
16	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice, 2021, 17, e1821-e1829.	1.4	4
17	The COVID-19 pandemic and new clinical trial activations. Trials, 2021, 22, 260.	0.7	37
18	Representativeness in Premarketing vs Postmarketing US Food and Drug Administration Trials. JAMA Network Open, 2021, 4, e217159.	2.8	1

#	Article	IF	CITATIONS
19	Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200) Journal of Clinical Oncology, 2021, 39, 12018-12018.	0.8	2
20	Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2118433.	2.8	35
21	Adolescent and young adult enrollment to a National Cancer Institute–sponsored National Clinical Trials Network Research Group over 25 years. Cancer, 2021, 127, 4574-4584.	2.0	11
22	Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. JCO Oncology Practice, 2021, 17, e1246-e1257.	1.4	8
23	Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 669-675.	1.1	35
24	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms. JNCI Cancer Spectrum, 2021, 5, pkab087.	1.4	2
25	Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls. Frontiers in Pharmacology, 2021, 12, .	1.6	12
26	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). Journal of Clinical Oncology, 2020, 38, 804-814.	0.8	142
27	Patterns of alcohol use and associated characteristics and HIV-related outcomes among a sample of African-American women living with HIV. Drug and Alcohol Dependence, 2020, 206, 107753.	1.6	12
28	Economic Evaluations in National Cancer Institute–Sponsored Network Cancer Clinical Trials. Value in Health, 2020, 23, 1653-1661.	0.1	2
29	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectrum, 2020, 4, pkaa034.	1.4	59
30	Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. Journal of Clinical Oncology, 2020, 38, 2122-2129.	0.8	59
31	Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. JAMA Network Open, 2020, 3, e2010651.	2.8	72
32	Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. Contemporary Clinical Trials, 2020, 95, 106037.	0.8	4
33	Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. JAMA Network Open, 2020, 3, e203842.	2.8	29
34	Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. Cancer Medicine, 2020, 9, 2146-2152.	1.3	18
35	What Keeps Patients Out of Clinical Trials?. JCO Oncology Practice, 2020, 16, 125-127.	1.4	16
36	Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. Breast Cancer Research and Treatment, 2020, 181, 455-463.	1.1	5

#	Article	IF	CITATIONS
37	Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. JAMA Network Open, 2020, 3, e2031202.	2.8	10
38	Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105) Journal of Clinical Oncology, 2020, 38, 12019-12019.	0.8	3
39	Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD Journal of Clinical Oncology, 2020, 38, 7010-7010.	0.8	8
40	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncology, 2019, 5, e191870.	3.4	348
41	A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events. Health and Quality of Life Outcomes, 2019, 17, 146.	1.0	2
42	Sociodemographic, clinical and birth hospitalization characteristics and infant Hepatitis B vaccination in Washington State. Vaccine, 2019, 37, 5738-5744.	1.7	11
43	Association between body mass index and response to duloxetine for aromatase inhibitorâ€associated musculoskeletal symptoms in SWOG S1202. Cancer, 2019, 125, 2123-2129.	2.0	18
44	Lung Cancer Screening in the National Cancer Institute Community Oncology Research Program: Availability and Service Organization. Journal of the American College of Radiology, 2019, 16, 427-434.	0.9	7
45	Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. Journal of the National Cancer Institute, 2019, 111, 245-255.	3.0	294
46	Association of National Cancer Institute–Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. JAMA Network Open, 2019, 2, e1910593.	2.8	18
47	Religiosity, Social Support, and Ethnic Identity: Exploring "Resilience Resources―for African-American Women Experiencing HIV-Related Stigma. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 175-183.	0.9	14
48	Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups. Cancer, 2019, 125, 1313-1318.	2.0	30
49	Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncology, 2019, 5, 497.	3.4	67
50	Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncology, 2019, 5, 326.	3.4	115
51	HIV-Related Stigma and Viral Suppression Among African-American Women: Exploring the Mediating Roles of Depression and ART Nonadherence. AIDS and Behavior, 2019, 23, 2025-2036.	1.4	43
52	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. Journal of the National Cancer Institute, 2019, 111, 210-213.	3.0	70
53	Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 324-330.	0.8	11
54	Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211 Journal of Clinical Oncology, 2019, 37, 11502-11502.	0.8	4

#	Article	IF	CITATIONS
55	Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2018, 110, 1208-1215.	3.0	16
56	Estimating global treatment toxicity burden from adverseâ€event data. Cancer, 2018, 124, 858-864.	2.0	7
57	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data. Journal of Clinical Oncology, 2018, 36, 1981-1990.	0.8	268
58	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. Journal of Clinical Oncology, 2018, 36, 2710-2717.	0.8	61
59	Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). Journal of Patient-Reported Outcomes, 2018, 2, 27.	0.9	10
60	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Research and Treatment, 2018, 172, 603-610.	1.1	37
61	Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of Clinical Oncology, 2018, 36, 326-332.	0.8	79
62	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiology, 2018, 55, 117-122.	0.8	3
63	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2018, 320, 167.	3.8	202
64	Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. JAMA Network Open, 2018, 1, e181235.	2.8	130
65	The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. JAMA Oncology, 2017, 3, 1345.	3.4	24
66	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. Journal of Clinical Oncology, 2017, 35, 804-805.	0.8	20
67	Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. Journal of Cancer Survivorship, 2017, 11, 32-40.	1.5	3
68	History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. JCO Clinical Cancer Informatics, 2017, 1, 1-12.	1.0	1
69	The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 185-198.	1.8	375
70	The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 185-198.	1.8	246
71	Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer—Reply. JAMA Oncology, 2016, 2, 686.	3.4	0
72	Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2016, 108, djw168.	3.0	36

#	Article	IF	CITATIONS
73	Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology—Reply. JAMA Oncology, 2016, 2, 1511.	3.4	2
74	The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. JAMA Oncology, 2016, 2, 875.	3.4	45
75	Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncology, 2016, 2, 453.	3.4	83
76	Patient Income Level and Cancer Clinical Trial Participation. JAMA Oncology, 2016, 2, 137.	3.4	123
77	lbritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood, 2015, 125, 236-241.	0.6	17
78	Ovarian Protection during Adjuvant Chemotherapy. New England Journal of Medicine, 2015, 372, 2268-2270.	13.9	39
79	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor–Induced Musculoskeletal Pain: SWOG S0927. Journal of Clinical Oncology, 2015, 33, 1910-1917.	0.8	83
80	The Diffusion of Docetaxel in Patients With Metastatic Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	17
81	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. New England Journal of Medicine, 2015, 372, 923-932.	13.9	452
82	Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials. Journal of the National Cancer Institute, 2014, 106, dju002.	3.0	178
83	<scp>R</scp> â€ <scp>CHOP</scp> with iodineâ€131 tositumomab consolidation for advanced stage diffuse large <scp>B</scp> â€cell lymphoma (<scp>DLBCL</scp>): <scp>SWOG S</scp> 0433. British Journal of Haematology, 2014, 166, 382-389.	1.2	33
84	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral Tâ€cell nonâ€Hodgkin lymphoma. Cancer, 2013, 119, 371-379.	2.0	74
85	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. New England Journal of Medicine, 2013, 369, 1681-1690.	13.9	298
86	Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Research and Treatment, 2013, 137, 903-913.	1.1	31
87	Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. Journal of Clinical Oncology, 2013, 31, 2627-2633.	0.8	184
88	Patient Income Level and Cancer Clinical Trial Participation. Journal of Clinical Oncology, 2013, 31, 536-542.	0.8	209
89	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab. Clinical Cancer Research, 2013, 19, 6624-6632.	3.2	32
90	A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316). Oncologist, 2012, 17, 1180-1190.	1.9	89

#	Article	IF	CITATIONS
91	A phase 2 trial of complete resection for stage IV melanoma. Cancer, 2011, 117, 4740-4746.	2.0	136
92	A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma. Blood, 2011, 118, 98-98.	0.6	14
93	A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma. PLoS ONE, 2011, 6, e22267.	1.1	9
94	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica, 2010, 95, 597-603.	1.7	87
95	Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516—The Southwest Oncology Group. Journal of Clinical Oncology, 2009, 27, 114-119.	0.8	226
96	Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897. Journal of Clinical Oncology, 2009, 27, 2157-2162.	0.8	100
97	â€~Minority report': how best to analyze clinical trial data to address disparities. Breast Cancer Research and Treatment, 2009, 118, 519-521.	1.1	2
98	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leukemia and Lymphoma, 2009, 50, 728-735.	0.6	84
99	Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. Journal of Clinical Oncology, 2008, 26, 2258-2263.	0.8	247
100	Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897. Journal of Clinical Oncology, 2008, 26, 1223-1230.	0.8	78
101	Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy. Journal of Clinical Oncology, 2008, 26, 112-120.	0.8	140
102	Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood, 2008, 111, 4048-4054.	0.6	25
103	Impact of a Peer-Delivered Telephone Intervention for Women Experiencing a Breast Cancer Recurrence. Journal of Clinical Oncology, 2007, 25, 2093-2099.	0.8	62
104	Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Laboratory Investigation, 2007, 87, 979-997.	1.7	50
105	Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials. Journal of Clinical Oncology, 2006, 24, 141-144.	0.8	105
106	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood, 2005, 107, 1101-1107.	0.6	68
107	Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer, 2005, 103, 1375-1380.	2.0	40
108	New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. Journal of Clinical Oncology, 2005, 23, 8447-8452.	0.8	368

#	Article	IF	CITATIONS
109	The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategiesâ~†. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 362-368.	0.8	13
110	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 2004, 103, 4251-4258.	0.6	296
111	Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014) Blood, 2004, 104, 158-158.	0.6	25
112	The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial. Biology of Blood and Marrow Transplantation, 2003, 9, 529-539.	2.0	55
113	A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood, 2003, 102, 1606-1612.	0.6	165
114	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group. Journal of Clinical Oncology, 2002, 20, 2058-2066.	0.8	206
115	Risk Assessment in Localized Primary Cutaneous Melanoma. American Journal of Clinical Pathology, 2002, 118, 504-511.	0.4	98
116	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome. Journal of Clinical Oncology, 2002, 20, 2067-2075.	0.8	197
117	Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2001, 19, 750-755.	0.8	29
118	Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin's Disease. Journal of Clinical Oncology, 2001, 19, 4238-4244.	0.8	143
119	Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin's Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809. Journal of Clinical Oncology, 2000, 18, 2010-2016.	0.8	74
120	Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. New England Journal of Medicine, 1999, 341, 2061-2067.	13.9	2,030
121	Cross ectional Versus Longitudinal Estimates of Cognitive Change in Nondemented Older People: A CERAD Study. Journal of the American Geriatrics Society, 1999, 47, 559-563.	1.3	45
122	Metastatic Melanoma From Intraocular Primary Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 568-572.	0.6	59